 
|
|
"NPS has a valuable royalty-based portfolio that includes four marketed products. While we have monetized some of these royalties as non-recourse debt, we believe the residual value of Sensipar alone represents significant value to NPS. This is often an underappreciated piece of our business."
Luke Beshar
Senior Vice President
Chief Financial Officer
| Partnered Pipeline |
|
The research and development capabilities of NPS have led to the discovery of a number of products that have been out-licensed. The result is a valuable royalty-generating portfolio that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil. |
|